Recent discussions on X about Plus Therapeutics (PSTV) have been ignited by the company’s announcement of a national coverage agreement with UnitedHealthcare for its CNSide cancer test, which has reportedly driven a significant surge in the stock price. Many users on the platform are expressing excitement over the deal’s potential to expand access to the diagnostic tool, reaching over 51 million individuals, and are speculating on its impact on the company’s growth in the biotech sector. The conversation reflects a strong interest in how this partnership could shape the stock’s future performance.
Additionally, there’s notable buzz on X surrounding Plus Therapeutics regaining Nasdaq compliance and securing a substantial grant to support its programs, further fueling discussions about the company’s financial stability. Some posts highlight optimism about the extended cash runway into the second half of 2025, while others remain cautious about past compliance challenges. This mix of enthusiasm and scrutiny keeps the dialogue dynamic and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
Plus Therapeutics Insider Trading Activity
Plus Therapeutics insiders have traded $PSTV stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PSTV stock by insiders over the last 6 months:
- ROBERT P LENK purchased 110,000 shares for an estimated $53,779
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Plus Therapeutics Hedge Fund Activity
We have seen 11 institutional investors add shares of Plus Therapeutics stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC added 117,454 shares (+inf%) to their portfolio in Q2 2025, for an estimated $40,850
- HRT FINANCIAL LP removed 102,065 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $35,498
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 80,505 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $27,999
- UBS GROUP AG added 54,201 shares (+162.1%) to their portfolio in Q2 2025, for an estimated $18,851
- VIRTU FINANCIAL LLC removed 40,030 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,922
- GOLDMAN SACHS GROUP INC added 26,753 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,304
- MILLENNIUM MANAGEMENT LLC added 24,233 shares (+inf%) to their portfolio in Q2 2025, for an estimated $8,428
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Plus Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 09/25/2025
- Maxim Group issued a "Buy" rating on 08/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/27/2025
- Ascendiant Capital issued a "Buy" rating on 06/05/2025
To track analyst ratings and price targets for Plus Therapeutics, check out Quiver Quantitative's $PSTV forecast page.
Plus Therapeutics Price Targets
Multiple analysts have issued price targets for $PSTV recently. We have seen 4 analysts offer price targets for $PSTV in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $5.0 on 09/25/2025
- Jason McCarthy from Maxim Group set a target price of $3.0 on 08/18/2025
- Sean Lee from HC Wainwright & Co. set a target price of $3.0 on 06/27/2025
- Edward Woo from Ascendiant Capital set a target price of $20.5 on 06/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
